Skadden advised GNI Group, a global biopharmaceutical group operating pharmaceutical/medtech businesses listed on the Tokyo Stock Exchange, on its ¥13.3 billion (approximately US$90 million) international common stock offering pursuant to Rule 144A/Regulation S.
The Tokyo-based corporate team was led by partner and head of Skadden’s Tokyo office Kenji Taneda and included counsel Ken Kiyota, Asia Pacific counsel Yuko Ozaki and associate Matthew Longarini.
